Home / Deep Research / X-linked Dystonia-Parkinsonism

X-linked Dystonia-Parkinsonism

X-linked Dystonia–Parkinsonism (XDP; “Lubag”) — Comprehensive Disease Characteristics Report

2026-06-03
Falcon MONDO:0010747 Model: Edison Scientific Literature 30 citations

X-linked Dystonia–Parkinsonism (XDP; “Lubag”) — Comprehensive Disease Characteristics Report

Target disease

Disease: X-linked dystonia–parkinsonism (XDP)
Category: Mendelian; X-linked (recessive) movement disorder
Key synonym set: DYT3; DYT/PARK-TAF1; “Lubag” (pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2, pozojevic2022factorsinfluencingreduced pages 1-2)

Executive summary (current understanding)

XDP is an adult-onset, progressive neurodegenerative movement disorder with a strong founder effect in individuals of Filipino ancestry, especially from Panay Island in the Philippines. Clinically, it most often begins as focal dystonia that generalizes over several years and later evolves toward combined dystonia–parkinsonism and then a parkinsonian-predominant phase in surviving patients. The causal variant is a founder SINE–VNTR–Alu (SVA) retrotransposon insertion in TAF1 intron 32 that disrupts TAF1 transcription and RNA processing; a polymorphic intronic (CCCTCT)n hexamer repeat within the SVA strongly modifies age at onset and shows tissue-specific somatic instability. Recent 2024 work provides mechanistic detail implicating (i) G-quadruplex formation within the amplified repeat domain and (ii) an innate epigenetic defense mediated by the KRAB zinc-finger protein ZNF91 that deposits H3K9me3/DNA methylation (“mini-heterochromatin”) over SVAs and modulates the XDP molecular phenotype. (nicoletto2024gquadruplexesinan pages 1-2, horvath2024miniheterochromatindomainsconstrain pages 1-2)

1. Disease information

1.1 What is the disease?

XDP is an adult-onset neurodegenerative movement disorder characterized by dystonia and parkinsonism, endemic to the Philippines with strong association to Panay Island and Filipino ancestry. It is X-linked and predominantly affects males. (jamora2023transcranialmagneticresonanceguided pages 1-2, pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2)

1.2 Key identifiers

1.3 Synonyms / alternative names

1.4 Evidence type note

The information synthesized here is derived from aggregated disease-level reviews and primary human studies, including patient-derived cell models, postmortem references, and clinical study protocols/registries. (nicoletto2024gquadruplexesinan pages 1-2, tshilenge2024proteomicanalysisof pages 1-2, jamora2023transcranialmagneticresonanceguided pages 1-2)

2. Etiology

2.1 Primary causal factors (genetic)

Causal locus and structural variant - XDP is caused by a founder SVA retrotransposon insertion in intron 32 of TAF1, with associated disruption of TAF1 RNA processing and expression. (tshilenge2024proteomicanalysisof pages 1-2, crombie2024therolesof pages 13-14)

Repeat feature within the SVA - The pathogenic SVA contains a polymorphic (CCCTCT)n hexameric repeat (often reported in the ~30–55 range), which correlates with disease expressivity/age at onset and is somatically unstable. (crombie2024therolesof pages 11-13, campion2022tissuespecificandrepeat pages 1-2)

2.2 Risk factors

2.3 Protective factors

No validated protective environmental or pharmacologic factors were identified in the retrieved evidence. Genetic “protective” alleles are implied via modifier loci (e.g., MSH3/PMS2) that delay onset. (pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4, campion2022tissuespecificandrepeat pages 1-2)

2.4 Gene–environment interactions

No specific gene–environment interaction evidence was found in the retrieved corpus.

3. Phenotypes

3.1 Core phenotype spectrum (with suggested HPO terms)

Dystonia (dominant early feature) - Typical presentation: focal dystonia that often generalizes within ~2–5 years. (pozojevic2022factorsinfluencingreduced pages 1-2, jamora2023transcranialmagneticresonanceguided pages 1-2) - Suggested HPO terms: Dystonia (HP:0001332); Focal dystonia (HP:0004370); Generalized dystonia (HP:0007256); Segmental dystonia (HP:0002540).

Distribution/frequencies (useful for knowledge base) - Craniocervical onset ~60%; limb onset ~37%; truncal ~4%. (pozojevic2022factorsinfluencingreduced pages 1-2) - Blepharospasm ~28%; mouth/tongue dystonia ~23%. (pozojevic2022factorsinfluencingreduced pages 1-2) - Suggested HPO terms: Cervical dystonia (HP:0001333); Blepharospasm (HP:0000520); Oromandibular dystonia (HP:0000180); Limb dystonia (HP:0002456); Truncal dystonia (HP:0002547).

Parkinsonism (often later; sometimes initial) - Parkinsonism can present initially (~14% in one summary) or typically emerges later, often beyond the ~10th year, with tremor, bradykinesia, and gait instability. (pozojevic2022factorsinfluencingreduced pages 1-2, jamora2023transcranialmagneticresonanceguided pages 1-2) - Suggested HPO terms: Parkinsonism (HP:0001300); Bradykinesia (HP:0002067); Gait instability (HP:0002317); Tremor (HP:0001337).

3.2 Age of onset / severity / progression

3.3 Quality of life impact

XDP is associated with poor quality of life and decreased life expectancy; the MRgFUS study protocol includes EQ-5D-5L as a QoL metric, reflecting clinical emphasis on functional impact. (jamora2023transcranialmagneticresonanceguided pages 1-2)

4. Genetic / molecular information

4.1 Causal gene(s)

4.2 Pathogenic variant type/class

4.3 Modifier genes

4.4 Epigenetic information

Multiple lines of evidence indicate epigenetic regulation at/around the SVA influences the molecular phenotype, including heterochromatin-based repression of SVAs (ZNF91-driven) and disease-related chromatin changes reversible by SVA excision in model systems. (horvath2024miniheterochromatindomainsconstrain pages 1-2, crombie2024therolesof pages 13-14)

5. Environmental information

No specific toxins, lifestyle factors, or infectious triggers were supported by retrieved evidence as contributors to XDP risk or progression.

6. Mechanism / pathophysiology

6.1 Causal chain (from variant to phenotype)

Upstream lesion: Founder SVA insertion (with amplified (CCCTCT)n repeat) in TAF1 intron 32 (tshilenge2024proteomicanalysisof pages 1-2).

Intermediate molecular effects (RNA + chromatin + transcription) 1) Aberrant TAF1 RNA processing: altered splicing with partial intron 32 retention and decreased transcription downstream of the insertion is repeatedly described across XDP neural models. (tshilenge2024proteomicanalysisof pages 1-2) 2) Cryptic exon/aberrant transcript: a disease-associated intronic exon (“32i”) produces TAF1−32i, disrupting the ORF and linked to premature termination/NMD in review synthesis. (crombie2024therolesof pages 13-14) 3) G-quadruplex mechanism (2024 primary advance): Nicoletto et al. (Nucleic Acids Research; advance access 17 Sep 2024; https://doi.org/10.1093/nar/gkae797) report that stable G4s form at the XDP SVA and modulate TAF1 transcription. Abstract quote: “Our data indicate that G4 formation in the XDP SVA is a major cause of aberrant TAF1 expression.” (nicoletto2024gquadruplexesinan pages 1-2) 4) Epigenetic repression / innate defense (2024 primary advance): Horváth et al. (Nature Structural & Molecular Biology; accepted 17 Apr 2024; https://doi.org/10.1038/s41594-024-01320-8) show ZNF91 establishes H3K9me3 and DNA methylation over SVAs; “removal of local heterochromatin severely aggravates the XDP molecular phenotype, resulting in increased TAF1 intron retention and reduced expression.” (horvath2024miniheterochromatindomainsconstrain pages 1-2) 5) Age-related modulation (2024): Rosenkrantz et al. (PNAS; published 5 Aug 2024; https://doi.org/10.1073/pnas.2401217121) report ZNF91 binds G4-prone DNA and propose age-related decline in ZNF91 may contribute to late onset; the paper describes ZNF91 binding to DNA with “high G4 propensity” and hypothesizes ZNF91 “binds to and prevents the formation of G4s…within the XDP-SVA.” (rosenkrantz2024znf91isan pages 1-2)

Downstream cellular/tissue pathology - Preferential vulnerability/degeneration of striatal medium spiny neurons (MSNs) and striatal atrophy (caudate/putamen). (tshilenge2024proteomicanalysisof pages 1-2, crombie2024therolesof pages 13-14) - Proteomics (2024) indicates broad dysregulation of RNA metabolism/splicing, mitochondrial function, chromatin assembly, and neurodegeneration-related pathways in patient-derived MSNs. (tshilenge2024proteomicanalysisof pages 1-2)

6.2 Molecular pathways and processes (suggested GO terms)

Representative GO biological process terms to support annotation (based on evidence above): - Regulation of transcription by RNA polymerase II; transcription initiation by RNA polymerase II (tshilenge2024proteomicanalysisof pages 2-4) - mRNA processing; RNA splicing; intron retention (tshilenge2024proteomicanalysisof pages 1-2, horvath2024miniheterochromatindomainsconstrain pages 1-2) - Nonsense-mediated mRNA decay (NMD) (crombie2024therolesof pages 13-14) - Chromatin-mediated transcriptional repression; establishment of H3K9 methylation; DNA methylation (horvath2024miniheterochromatindomainsconstrain pages 1-2) - Mitochondrial function / mitochondrial disassembly (tshilenge2024proteomicanalysisof pages 1-2)

6.3 Cell types (suggested CL terms)

6.4 Anatomical structures (suggested UBERON terms)

6.5 Visual evidence (locus + intron retention)

Figure evidence from Horváth et al. shows the TAF1 locus with the XDP SVA insertion and RNA-seq tracks illustrating intron 32 retention in XDP NPC models. (horvath2024miniheterochromatindomainsconstrain media 7af698dd)

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

10.1 Clinical diagnosis

Suspect XDP in adult-onset focal-to-generalized dystonia with evolving parkinsonism in individuals with Filipino/Panay ancestry or relevant family history. (jamora2023transcranialmagneticresonanceguided pages 1-2)

10.2 Genetic testing (confirmatory)

10.3 Molecular/omics assays used in recent research (informing diagnostic biomarker development)

10.4 Differential diagnosis

Differential diagnosis content (distinguishing from other dystonia-parkinsonism syndromes) was not comprehensively retrievable from the current evidence set.

11. Outcome / prognosis

12. Treatment

12.1 Symptomatic pharmacotherapy and chemodenervation (real-world practice)

Jamora et al. (BMC Neurology; Aug 2023; https://doi.org/10.1186/s12883-023-03344-x) list oral medications used symptomatically (e.g., carbidopa/levodopa, trihexyphenidyl, biperiden, haloperidol, diazepam, zolpidem, milacemide, anticonvulsants, antihistamines), noting variable/suboptimal response. Botulinum toxin A and muscle afferent blockade are also used. (jamora2023transcranialmagneticresonanceguided pages 1-2)

Suggested MAXO terms (examples): pharmacotherapy; levodopa therapy; anticholinergic therapy; benzodiazepine therapy; botulinum toxin injection; supportive care.

12.2 Deep brain stimulation (DBS)

DBS has been reported as “immediately effective and robust” for alleviating debilitating XDP symptoms, but is costly and often unaffordable in endemic settings. (jamora2023transcranialmagneticresonanceguided pages 2-4)

Suggested MAXO term: deep brain stimulation.

12.3 Ablative and incisionless interventions: MR-guided focused ultrasound (MRgFUS)

Rationale and protocolized implementation (2023–ongoing): - Jamora et al. describe a prospective MRgFUS pallidothalamic tractotomy protocol at Philippine General Hospital using XDP-MDSP as primary outcome and BFMDRS + MDS-UPDRS Part III as additional measures; the protocol is registered as NCT05592028 and includes EQ-5D-5L and MoCA. (jamora2023transcranialmagneticresonanceguided pages 1-2, NCT05592028 chunk 1)

Clinical outcomes (small series): - Four genetically confirmed Filipino XDP patients treated with MRgFUS pallidothalamic tract lesioning reported ~30–36% improvement in XDP-MDSP scores at 6 months and 1 year (as summarized in the protocol paper). (jamora2023transcranialmagneticresonanceguided pages 1-2)

Suggested MAXO terms: MR-guided focused ultrasound ablation; pallidothalamic tractotomy.

12.4 Experimental / precision-medicine directions (preclinical)

Recent mechanistic work suggests several therapeutic hypotheses: - Targeting G-quadruplex structures to restore TAF1 transcriptional output (nicoletto2024gquadruplexesinan pages 1-2) - Modulating SVA repression pathways (ZNF91/heterochromatin) (horvath2024miniheterochromatindomainsconstrain pages 1-2) - Correcting aberrant splicing and/or directly excising the SVA (CRISPR rescue in model systems cited in reviews/primary summaries) (pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4, crombie2024therolesof pages 13-14)

13. Prevention

14. Other species / natural disease

No naturally occurring XDP-like disease in non-human species was identified in the retrieved evidence.

15. Model organisms / model systems

15.1 Human cellular models (high relevance)

15.2 Non-human models

A mouse knockdown model affecting nTaf1 is mentioned in review-level synthesis as producing motor defects, but detailed model phenotyping was not available in the retrieved evidence set. (crombie2024therolesof pages 11-13)

Recent developments (prioritizing 2023–2024)

1) G-quadruplex-driven transcriptional dysregulation: Nucleic Acids Research (Sept 2024) provides experimental evidence that stable G4s form within the XDP SVA in patient cells and that pharmacologic stabilization/destabilization shifts TAF1 transcript patterns. (nicoletto2024gquadruplexesinan pages 1-2) 2) Innate epigenetic defense against SVAs: Nature Structural & Molecular Biology (June 2024) shows ZNF91-dependent mini-heterochromatin (H3K9me3 + DNA methylation) constrains SVA cis-regulatory effects and that loss of local heterochromatin worsens TAF1 intron retention/expression in XDP NPCs. (horvath2024miniheterochromatindomainsconstrain pages 1-2) 3) Proteome-level signatures in striatal neurons: Neurobiology of Disease (Jan 2024) describes pathway enrichments implicating RNA metabolism/splicing and mitochondrial/chromatin processes in patient-derived MSNs, reinforcing RNA-processing as a central disease axis. (tshilenge2024proteomicanalysisof pages 1-2) 4) Clinical translation efforts in endemic regions: BMC Neurology (Aug 2023) protocol and ClinicalTrials.gov expanded-access listing reflect real-world implementation of MRgFUS pallidothalamic tractotomy with XDP-specific outcome measures. (jamora2023transcranialmagneticresonanceguided pages 1-2, NCT05592028 chunk 1)

Current applications / real-world implementations

Clinical trials and registries (URLs + key metadata)

  • NCT05592028 (Expanded Access; AVAILABLE): “High Intensity Focused Ultrasound for X-linked Dystonia-parkinsonism” (MRgFUS pallidothalamic tractotomy; PGH, Philippines). Outcomes include XDP-MDSP, XDP staging, BFMDRS, UPDRS with follow-up through 12 months. (NCT05592028 chunk 1)
  • NCT03019458 (Completed; 50 participants): “MINGO Supplemental Trial in X-linked Dystonia-Parkinsonism Patients” (nutritional supplement; BMI primary endpoint; Roxas City, Philippines). (NCT03019458 chunk 1)
  • NCT05713721 (Observational; includes DYT/PARK-TAF1 arm): sensorimotor integration study including DBS on/off evaluation in symptomatic carriers; neurophysiology via TMS short-latency afferent inhibition and blinded video ratings. (NCT05713721 chunk 2)

Statistics and data highlights (human studies)

Structured summary table

Table (click to expand)
Domain Key facts Evidence type Key citations
Identifiers X-linked dystonia-parkinsonism (XDP); synonyms: DYT/PARK-TAF1, DYT3, Lubag; OMIM #314250; adult-onset X-linked neurodegenerative movement disorder, endemic in the Philippines/Panay founder population Review (pozojevic2022factorsinfluencingreduced pages 1-2, pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2)
Genetics Causal lesion is a ~2.6 kb SINE-VNTR-Alu (SVA) retrotransposon inserted in intron 32 of TAF1 on Xq13.1; all probands share a founder haplotype around TAF1; CRISPR excision of the SVA restores TAF1 mRNA in model cells Review + primary (pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2, crombie2024therolesof pages 1-2, pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4)
Repeat feature The pathogenic SVA contains a polymorphic hexameric (CCCTCT)n repeat; typical reported range ~30–55 repeats, with amplified HEX tract compared with typical SVAs; repeat length inversely correlates with age at onset and age at death Review + primary (nicoletto2024gquadruplexesinan pages 1-2, campion2022tissuespecificandrepeat pages 1-2, crombie2024therolesof pages 11-13, pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4)
Modifiers Each additional hexamer repeat shortens age at onset by ~1.4 years in larger cohorts; repeat length explained ~50% of age-at-onset variance initially, and repeat plus known modifiers explain only ~65%, implying additional factors Review (pozojevic2022xlinkeddystoniaparkinsonismover pages 4-5)
DNA repair modifiers MSH3 and PMS2 modify age-associated penetrance/expressivity; protective alleles delay onset; findings link XDP to repeat-instability biology shared with Huntington disease Review + primary (pozojevic2022factorsinfluencingreduced pages 1-2, campion2022tissuespecificandrepeat pages 1-2, crombie2024therolesof pages 14-16, pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4)
Inheritance / penetrance X-linked recessive; predominantly affects Filipino males; rare affected females occur via homozygosity, skewed X-inactivation, or aneuploidy; penetrance is age-dependent Review (pozojevic2022factorsinfluencingreduced pages 1-2, crombie2024therolesof pages 14-16)
Epidemiology Endemic on Panay island, Philippines; reported prevalence ~5.74 per 100,000 in Panay; strong founder effect with indigenous Philippine haplotype Review + primary summary (pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2, tshilenge2024proteomicanalysisof pages 1-2)
Age at onset Median/average onset ~39–40 years; reported onset range 20–67 years; disease is chronic, progressive, and fatal Review + primary (pozojevic2022factorsinfluencingreduced pages 1-2, campion2022tissuespecificandrepeat pages 1-2, crombie2024therolesof pages 11-13)
Core clinical phenotype >80% present with focal dystonia; dystonia is initial feature in ~93% in some series; onset distribution ~60% craniocervical, ~37% limb, ~4% truncal; dystonia typically generalizes within 5 years (5–10 years in some reviews), then parkinsonism may emerge and later predominate Review (pozojevic2022factorsinfluencingreduced pages 1-2, pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2, crombie2024therolesof pages 11-13)
Morbidity / outcome Severe disability is common; aspiration contributes to premature death; mean age at death reported ~55.6 years; no obvious correlation between repeat length and disease duration in one primary study Review + primary (pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2, campion2022tissuespecificandrepeat pages 1-2, crombie2024therolesof pages 11-13)
Neuropathology Preferential degeneration of striatal medium spiny neurons with caudate/putaminal atrophy; iron accumulation in anteromedial putamen reported; subventricular zone neural progenitor loss also described Review + primary/review (pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2, crombie2024therolesof pages 11-13, tshilenge2024proteomicanalysisof pages 1-2)
Molecular mechanism: TAF1 XDP SVA is associated with reduced/aberrant TAF1 expression, altered splicing, partial intron 32 retention, and disease-associated transcript TAF1-32i from cryptic exon 32i that disrupts the ORF and can trigger nonsense-mediated decay Review + primary (tshilenge2024proteomicanalysisof pages 1-2, crombie2024therolesof pages 13-14)
Mechanism: G-quadruplexes G-rich XDP SVA sequences form stable G-quadruplexes in vitro and in patient fibroblasts/NPCs; G4 stabilization (BRACO-19, quarfloxin) reduces downstream TAF1 transcripts and increases upstream transcripts, while G4 destabilization (PhpC) increases TAF1 transcripts Primary (nicoletto2024gquadruplexesinan pages 1-2)
Mechanism: epigenetic repression ZNF91 binds SVAs and, with TRIM28, helps establish local mini-heterochromatin marked by H3K9me3 and DNA methylation; removing this repression worsens the XDP molecular phenotype, increasing TAF1 intron retention and reducing TAF1 expression Primary (horvath2024miniheterochromatindomainsconstrain pages 10-11, horvath2024miniheterochromatindomainsconstrain pages 1-2)
Mechanism: aging modifier ZNF91 expression declines with age in brain/blood; reported associations include frontal cortex dR2 = -0.10354 (P = 2.02E-06), cerebellum dR2 = -0.0484 (P = 5.79E-04), nucleus accumbens dR2 = -0.05257 (P = 0.0003); this may help explain late onset Primary (rosenkrantz2024znf91isan pages 8-9, rosenkrantz2024znf91isan pages 7-8)
Somatic instability Repeat instability is expansion-biased, length-dependent, and tissue-specific; brain shows greater expansion than blood; cortical regions show relatively high instability, cerebellum low instability; observed changes range from small shifts (up to ±5 repeats) to rarer large expansions (~20 to >100 repeats) and contractions (~20–40 repeats) Primary (campion2022tissuespecificandrepeat pages 1-2)
Molecular profiling Proteomics in patient-derived striatal neurons/MSNs shows altered RNA metabolism, splicing, mitochondrial pathways, chromatin assembly, and overlap with neurodegeneration networks; TAF1, YY1, ATF2, USF1, and MYC emerged as enriched regulators Primary (tshilenge2024proteomicanalysisof pages 1-2)
Biomarkers Disease-specific TAF1 intron-retention / TAF1-32i transcripts are candidate molecular biomarkers; reviews also cite neurofilament light chain as a proposed biomarker direction, but validated clinical biomarker use remains limited Review + primary (crombie2024therolesof pages 13-14, pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4, pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2)
Diagnostics Diagnosis integrates characteristic phenotype, Panay/Filipino ancestry or family history, and confirmatory genetic testing for the TAF1 intron 32 SVA insertion/associated haplotype; repeat sizing and long-read/nanopore approaches are relevant for research and may aid molecular characterization Review (pozojevic2022factorsinfluencingreduced pages 1-2, pozojevic2022xlinkeddystoniaparkinsonismover pages 5-6, crombie2024therolesof pages 11-13)
Intervention landscape Current care is largely symptomatic/supportive; mechanistically motivated experimental avenues include SVA excision, splicing correction, G4 destabilization, and modulation of epigenetic repressors/TAF1 expression Review + primary (nicoletto2024gquadruplexesinan pages 1-2, crombie2024therolesof pages 13-14, pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4)
Trial: focused ultrasound NCT05592028: MR-guided focused ultrasound pallidothalamic tractotomy, expanded access, AVAILABLE; adult genetically confirmed male XDP; outcomes include XDP-MDSP scale, XDP clinical/functional staging, BFMDRS, UPDRS with follow-up to 12 months Clinical trial registry (NCT05592028 chunk 1)
Trial: nutritional support NCT03019458: MINGO supplement trial, randomized open-label, COMPLETED, n = 50; intervention = moringa/rice/mung-bean supplement for 12 weeks; primary endpoint = BMI; secondary endpoints = mortality, infectious-cause hospitalizations, MUAC Clinical trial registry (NCT03019458 chunk 1)
Trial: sensorimotor / DBS assessment NCT05713721: observational sensorimotor integration study including DYT/PARK-TAF1 carriers; evaluates TMS short-latency afferent inhibition, video-based clinical outcomes, and effects of deep brain stimulation on/off in symptomatic participants Clinical trial registry (NCT05713721 chunk 2, NCT05713721 chunk 1)

Table: This table condenses the main structured facts about X-linked dystonia-parkinsonism across identifiers, genetics, modifiers, epidemiology, clinical features, mechanisms, biomarkers, and current trial activity. It is designed to support rapid knowledge-base population while preserving traceability to the gathered evidence.

Key limitations of this synthesis (evidence gaps)

  • Orphanet/MONDO/MeSH/ICD identifiers were not recoverable from the tool-accessible corpus and should be added from external ontology resources.
  • Detailed, standardized diagnostic criteria and differential diagnosis algorithms were not present in retrieved sources.
  • Many mechanistic and therapeutic directions (e.g., splicing-targeted ASOs, gene editing) are supported primarily by cell-model work referenced in reviews; additional clinical translation evidence was not retrievable here.

References

  1. (pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2): Jelena Pozojevic, Joseph Neos Cruz, and Ana Westenberger. X-linked dystonia-parkinsonism: over and above a repeat disorder. Medizinische Genetik, 33:319-324, Dec 2022. URL: https://doi.org/10.1515/medgen-2021-2105, doi:10.1515/medgen-2021-2105. This article has 8 citations.

  2. (pozojevic2022factorsinfluencingreduced pages 1-2): J. Pozojevic, Björn-Hergen Laabs von Holt, and A. Westenberger. Factors influencing reduced penetrance and variable expressivity in x-linked dystonia-parkinsonism. Medizinische Genetik, 34:97-102, Jun 2022. URL: https://doi.org/10.1515/medgen-2022-2135, doi:10.1515/medgen-2022-2135. This article has 4 citations.

  3. (nicoletto2024gquadruplexesinan pages 1-2): Giulia Nicoletto, Marianna Terreri, Ilaria Maurizio, Emanuela Ruggiero, Filippo M Cernilogar, Christine A Vaine, Maria Vittoria Cottini, Irina Shcherbakova, Ellen B Penney, Irene Gallina, David Monchaud, D Cristopher Bragg, Gunnar Schotta, and Sara N Richter. G-quadruplexes in an sva retrotransposon cause aberrant taf1 gene expression in x-linked dystonia parkinsonism. Nucleic Acids Research, 52:11571-11586, Sep 2024. URL: https://doi.org/10.1093/nar/gkae797, doi:10.1093/nar/gkae797. This article has 26 citations and is from a highest quality peer-reviewed journal.

  4. (horvath2024miniheterochromatindomainsconstrain pages 1-2): Vivien Horváth, Raquel Garza, Marie E. Jönsson, Pia A. Johansson, Anita Adami, Georgia Christoforidou, Ofelia Karlsson, Laura Castilla Vallmanya, Symela Koutounidou, Patricia Gerdes, Ninoslav Pandiloski, Christopher H. Douse, and Johan Jakobsson. Mini-heterochromatin domains constrain the cis-regulatory impact of sva transposons in human brain development and disease. Nature Structural & Molecular Biology, 31:1543-1556, Jun 2024. URL: https://doi.org/10.1038/s41594-024-01320-8, doi:10.1038/s41594-024-01320-8. This article has 25 citations and is from a highest quality peer-reviewed journal.

  5. (jamora2023transcranialmagneticresonanceguided pages 1-2): Roland Dominic G. Jamora, Kathleen Joy O. Khu, Marie Charmaine C. Sy, Juan Silvestre G. Pascual, Gerardo D. Legaspi, and Jose A. Aguilar. Transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy for patients with x-linked dystonia-parkinsonism: a study protocol. BMC Neurology, Aug 2023. URL: https://doi.org/10.1186/s12883-023-03344-x, doi:10.1186/s12883-023-03344-x. This article has 8 citations and is from a peer-reviewed journal.

  6. (campion2022tissuespecificandrepeat pages 1-2): Lindsey N. Campion, Alan Mejia Maza, Rachita Yadav, Ellen B. Penney, Micaela G. Murcar, Kevin Correia, Tammy Gillis, Cara Fernandez-Cerado, M. Salvie Velasco-Andrada, G. Paul Legarda, Niecy G. Ganza-Bautista, J. Benedict B. Lagarde, Patrick J. Acuña, Trisha Multhaupt-Buell, Gabrielle Aldykiewicz, Melanie L. Supnet, Jan K. De Guzman, Criscely Go, Nutan Sharma, Edwin L. Munoz, Mark C. Ang, Cid Czarina E. Diesta, D. Cristopher Bragg, Laurie J. Ozelius, and Vanessa C. Wheeler. Tissue-specific and repeat length-dependent somatic instability of the x-linked dystonia parkinsonism-associated ccctct repeat. Acta Neuropathologica Communications, Apr 2022. URL: https://doi.org/10.1186/s40478-022-01349-0, doi:10.1186/s40478-022-01349-0. This article has 19 citations and is from a peer-reviewed journal.

  7. (tshilenge2024proteomicanalysisof pages 1-2): Kizito-Tshitoko Tshilenge, Joanna Bons, Carlos Galicia Aguirre, Cristian Geronimo-Olvera, Samah Shah, Jacob Rose, Akos A. Gerencser, Sally K. Mak, Michelle E. Ehrlich, D. Cristopher Bragg, Birgit Schilling, and Lisa M. Ellerby. Proteomic analysis of x-linked dystonia parkinsonism disease striatal neurons reveals altered rna metabolism and splicing. Jan 2024. URL: https://doi.org/10.1016/j.nbd.2023.106367, doi:10.1016/j.nbd.2023.106367. This article has 13 citations and is from a domain leading peer-reviewed journal.

  8. (crombie2024therolesof pages 13-14): Elisa M. Crombie, Karen Cleverley, H. T. Marc Timmers, and Elizabeth M. C. Fisher. The roles of taf1 in neuroscience and beyond. Royal Society Open Science, Sep 2024. URL: https://doi.org/10.1098/rsos.240790, doi:10.1098/rsos.240790. This article has 15 citations and is from a peer-reviewed journal.

  9. (crombie2024therolesof pages 11-13): Elisa M. Crombie, Karen Cleverley, H. T. Marc Timmers, and Elizabeth M. C. Fisher. The roles of taf1 in neuroscience and beyond. Royal Society Open Science, Sep 2024. URL: https://doi.org/10.1098/rsos.240790, doi:10.1098/rsos.240790. This article has 15 citations and is from a peer-reviewed journal.

  10. (pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4): Jelena Pozojevic, Joseph Neos Cruz, and Ana Westenberger. X-linked dystonia-parkinsonism: over and above a repeat disorder. Medizinische Genetik, 33:319-324, Dec 2022. URL: https://doi.org/10.1515/medgen-2021-2105, doi:10.1515/medgen-2021-2105. This article has 8 citations.

  11. (crombie2024therolesof pages 1-2): Elisa M. Crombie, Karen Cleverley, H. T. Marc Timmers, and Elizabeth M. C. Fisher. The roles of taf1 in neuroscience and beyond. Royal Society Open Science, Sep 2024. URL: https://doi.org/10.1098/rsos.240790, doi:10.1098/rsos.240790. This article has 15 citations and is from a peer-reviewed journal.

  12. (rosenkrantz2024znf91isan pages 1-2): Jimi L. Rosenkrantz, J. Elias Brandorff, Sanaz Raghib, Ashni Kapadia, Christine A. Vaine, D. Cristopher Bragg, Grace Farmiloe, and Frank M. J. Jacobs. Znf91 is an endogenous repressor of the molecular phenotype associated with x-linked dystonia–parkinsonism (xdp). Proceedings of the National Academy of Sciences of the United States of America, Aug 2024. URL: https://doi.org/10.1073/pnas.2401217121, doi:10.1073/pnas.2401217121. This article has 8 citations and is from a highest quality peer-reviewed journal.

  13. (tshilenge2024proteomicanalysisof pages 2-4): Kizito-Tshitoko Tshilenge, Joanna Bons, Carlos Galicia Aguirre, Cristian Geronimo-Olvera, Samah Shah, Jacob Rose, Akos A. Gerencser, Sally K. Mak, Michelle E. Ehrlich, D. Cristopher Bragg, Birgit Schilling, and Lisa M. Ellerby. Proteomic analysis of x-linked dystonia parkinsonism disease striatal neurons reveals altered rna metabolism and splicing. Jan 2024. URL: https://doi.org/10.1016/j.nbd.2023.106367, doi:10.1016/j.nbd.2023.106367. This article has 13 citations and is from a domain leading peer-reviewed journal.

  14. (horvath2024miniheterochromatindomainsconstrain media 7af698dd): Vivien Horváth, Raquel Garza, Marie E. Jönsson, Pia A. Johansson, Anita Adami, Georgia Christoforidou, Ofelia Karlsson, Laura Castilla Vallmanya, Symela Koutounidou, Patricia Gerdes, Ninoslav Pandiloski, Christopher H. Douse, and Johan Jakobsson. Mini-heterochromatin domains constrain the cis-regulatory impact of sva transposons in human brain development and disease. Nature Structural & Molecular Biology, 31:1543-1556, Jun 2024. URL: https://doi.org/10.1038/s41594-024-01320-8, doi:10.1038/s41594-024-01320-8. This article has 25 citations and is from a highest quality peer-reviewed journal.

  15. (crombie2024therolesof pages 14-16): Elisa M. Crombie, Karen Cleverley, H. T. Marc Timmers, and Elizabeth M. C. Fisher. The roles of taf1 in neuroscience and beyond. Royal Society Open Science, Sep 2024. URL: https://doi.org/10.1098/rsos.240790, doi:10.1098/rsos.240790. This article has 15 citations and is from a peer-reviewed journal.

  16. (NCT05592028 chunk 1): Roland Dominic G. Jamora. High Intensity Focused Ultrasound for X-linked Dystonia-parkinsonism. University of the Philippines Manila - Philippine General Hospital. ClinicalTrials.gov Identifier: NCT05592028

  17. (jamora2023transcranialmagneticresonanceguided pages 2-4): Roland Dominic G. Jamora, Kathleen Joy O. Khu, Marie Charmaine C. Sy, Juan Silvestre G. Pascual, Gerardo D. Legaspi, and Jose A. Aguilar. Transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy for patients with x-linked dystonia-parkinsonism: a study protocol. BMC Neurology, Aug 2023. URL: https://doi.org/10.1186/s12883-023-03344-x, doi:10.1186/s12883-023-03344-x. This article has 8 citations and is from a peer-reviewed journal.

  18. (NCT03019458 chunk 1): MINGO Supplemental Trial in X-linked Dystonia-Parkinsonism Patients. Sunshine Care Foundation. 2017. ClinicalTrials.gov Identifier: NCT03019458

  19. (NCT05713721 chunk 2): Anne Weißbach. Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes. University Hospital Schleswig-Holstein. 2023. ClinicalTrials.gov Identifier: NCT05713721

  20. (pozojevic2022xlinkeddystoniaparkinsonismover pages 4-5): Jelena Pozojevic, Joseph Neos Cruz, and Ana Westenberger. X-linked dystonia-parkinsonism: over and above a repeat disorder. Medizinische Genetik, 33:319-324, Dec 2022. URL: https://doi.org/10.1515/medgen-2021-2105, doi:10.1515/medgen-2021-2105. This article has 8 citations.

  21. (horvath2024miniheterochromatindomainsconstrain pages 10-11): Vivien Horváth, Raquel Garza, Marie E. Jönsson, Pia A. Johansson, Anita Adami, Georgia Christoforidou, Ofelia Karlsson, Laura Castilla Vallmanya, Symela Koutounidou, Patricia Gerdes, Ninoslav Pandiloski, Christopher H. Douse, and Johan Jakobsson. Mini-heterochromatin domains constrain the cis-regulatory impact of sva transposons in human brain development and disease. Nature Structural & Molecular Biology, 31:1543-1556, Jun 2024. URL: https://doi.org/10.1038/s41594-024-01320-8, doi:10.1038/s41594-024-01320-8. This article has 25 citations and is from a highest quality peer-reviewed journal.

  22. (rosenkrantz2024znf91isan pages 8-9): Jimi L. Rosenkrantz, J. Elias Brandorff, Sanaz Raghib, Ashni Kapadia, Christine A. Vaine, D. Cristopher Bragg, Grace Farmiloe, and Frank M. J. Jacobs. Znf91 is an endogenous repressor of the molecular phenotype associated with x-linked dystonia–parkinsonism (xdp). Proceedings of the National Academy of Sciences of the United States of America, Aug 2024. URL: https://doi.org/10.1073/pnas.2401217121, doi:10.1073/pnas.2401217121. This article has 8 citations and is from a highest quality peer-reviewed journal.

  23. (rosenkrantz2024znf91isan pages 7-8): Jimi L. Rosenkrantz, J. Elias Brandorff, Sanaz Raghib, Ashni Kapadia, Christine A. Vaine, D. Cristopher Bragg, Grace Farmiloe, and Frank M. J. Jacobs. Znf91 is an endogenous repressor of the molecular phenotype associated with x-linked dystonia–parkinsonism (xdp). Proceedings of the National Academy of Sciences of the United States of America, Aug 2024. URL: https://doi.org/10.1073/pnas.2401217121, doi:10.1073/pnas.2401217121. This article has 8 citations and is from a highest quality peer-reviewed journal.

  24. (pozojevic2022xlinkeddystoniaparkinsonismover pages 5-6): Jelena Pozojevic, Joseph Neos Cruz, and Ana Westenberger. X-linked dystonia-parkinsonism: over and above a repeat disorder. Medizinische Genetik, 33:319-324, Dec 2022. URL: https://doi.org/10.1515/medgen-2021-2105, doi:10.1515/medgen-2021-2105. This article has 8 citations.

  25. (NCT05713721 chunk 1): Anne Weißbach. Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes. University Hospital Schleswig-Holstein. 2023. ClinicalTrials.gov Identifier: NCT05713721

Artifacts